Moleculin Biotech, Inc. (MBRX) Total liabilities 2016–2025
Moleculin Biotech, Inc. (MBRX) total liabilities at each fiscal year-end, per SEC filings.
$7.1MFY2025 · since FY2016: $1.4M → $7.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $7.1M | +24.5% |
| FY2024 | $5.7M | -52.9% |
| FY2023 | $12.1M | +132.2% |
| FY2022 | $5.2M | +2.6% |
| FY2021 | $5.1M | -54.8% |
| FY2020 | $11.3M | +16.6% |
| FY2019 | $9.7M | +81.9% |
| FY2018 | $5.3M | +124.7% |
| FY2017 | $2.4M | +65.0% |
| FY2016 | $1.4M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice